Dorman Products Posts Record Q2 Earnings, Lifts EPS Guidance While Trimming Revenue Outlook
DORM sits 40% above its 52-week low of $98.445 on elevated volume (2.6× avg).
Summary
Dorman Products reported Q2 2026 diluted EPS of $2.93, a 53% year-over-year surge, and raised its full-year EPS guidance to $7.93–$8.23, while lowering revenue growth expectations to 3%–5%.
Key Events · Earnings and Guidance · DORM
-
Q2 Earnings Beat on Tariff Recovery
Diluted EPS hit $2.93, up 53% year over year, propelled by a $44.4 million IEEPA tariff cost recovery that lifted gross margin to 46.1% from 40.6%. Excluding this one-time benefit, adjusted diluted EPS was $1.90.
-
Strong Cash Flow and Buybacks
Operating cash flow came in at $152.6 million for the quarter, while $47 million in share repurchases reduced the diluted share count to 30.0 million from 30.7 million a year ago.
-
Full-Year Revenue Guidance Cut
The 2026 net sales growth outlook was lowered to 3%–5% from 7%–9%, reflecting tariff impacts and a more cautious demand environment, even as Q2 sales edged up just 0.7%.
-
EPS Guidance Raised on Margin Strength
Full-year diluted EPS guidance was raised to $7.93–$8.23 (from $7.57–$7.97), as improved gross margins, cost controls, and share repurchases partially offset the revenue shortfall.
Analysis · DORM · Manufacturing
A standout second quarter saw diluted EPS leap 53% to $2.93, fueled by a one-time IEEPA tariff recovery that added 820 basis points to gross margin. Operating cash flow reached $152.6 million, and $47 million in share repurchases further bolstered per-share results. Yet the full-year revenue growth forecast was slashed to 3%–5% from 7%–9%, as tariff and demand headwinds persist. EPS guidance, however, was raised to $7.93–$8.23 (up from $7.57–$7.97), with margin recovery and buybacks offsetting the softer top line. The divergence—lower sales but higher earnings—will be the central debate for investors.
At the time of this filing, DORM was trading at $137.90 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $98.45 to $166.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.